Middle East Healthcare Company vs Dr. Sulaiman Al Habib Medical S
A head-to-head of Middle East Healthcare Company (4009) and Dr. Sulaiman Al Habib Medical S (4013) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
Middle East Healthcare Company
4009
31.86 SAR
+0.19%
VS
Dr. Sulaiman Al Habib Medical S
4013
215.10 SAR
+1.27%
| Metric | 4009 | 4013 |
|---|---|---|
| Market Cap | 3.13B SAR | 75.29B SAR |
| P/E (TTM) | 9.71 | 31.36 |
| Forward P/E | 8.52 | 28.64 |
| P/S | 1.00 | 5.45 |
| P/B | 1.54 | 9.47 |
| EV/EBITDA | — | 26.07 |
| Dividend Yield | 1.47% | 1.85% |
| Profit Margin | 5.34% | 16.79% |
| Gross Margin | 37.39% | 30.69% |
| Operating Margin | 12.67% | 19.26% |
| Revenue Growth (YoY) | +4.29% | +8.80% |
| FCF Yield | 9.73% | 0.81% |
| Debt / Equity | 123.07 | 113.79 |
| Current Ratio | 1.48 | 1.14 |
Which is better: Middle East Healthcare Company or Dr. Sulaiman Al Habib Medical S?
- ✓Larger by market cap: Dr. Sulaiman Al Habib Medical S
- ✓Cheaper valuation (lower P/E): Middle East Healthcare Company
- ✓Higher dividend yield: Dr. Sulaiman Al Habib Medical S
- ✓More profitable (net margin): Dr. Sulaiman Al Habib Medical S
- ✓Faster revenue growth: Dr. Sulaiman Al Habib Medical S
- ✓Higher free-cash-flow yield: Middle East Healthcare Company
Across 12 available metrics, Middle East Healthcare Company leads 7–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Middle East Healthcare Company with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.